CN108261472A - 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 - Google Patents
含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 Download PDFInfo
- Publication number
- CN108261472A CN108261472A CN201810142339.3A CN201810142339A CN108261472A CN 108261472 A CN108261472 A CN 108261472A CN 201810142339 A CN201810142339 A CN 201810142339A CN 108261472 A CN108261472 A CN 108261472A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- matrimony vine
- chrysanthemum
- theanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 53
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 title claims abstract description 50
- 244000241838 Lycium barbarum Species 0.000 title claims abstract description 45
- 235000015459 Lycium barbarum Nutrition 0.000 title claims abstract description 45
- 235000007516 Chrysanthemum Nutrition 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 28
- 229940026510 theanine Drugs 0.000 title claims abstract description 25
- 244000189548 Chrysanthemum x morifolium Species 0.000 title 1
- 208000024891 symptom Diseases 0.000 claims abstract description 38
- 241000723353 Chrysanthemum Species 0.000 claims abstract description 37
- 210000001508 eye Anatomy 0.000 claims abstract description 34
- 239000000470 constituent Substances 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 210000005036 nerve Anatomy 0.000 claims abstract description 7
- 239000000047 product Substances 0.000 claims description 17
- 235000009508 confectionery Nutrition 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 10
- 244000246386 Mentha pulegium Species 0.000 claims description 7
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 7
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 7
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 7
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- 229960002747 betacarotene Drugs 0.000 claims description 7
- 235000001050 hortel pimenta Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 230000035807 sensation Effects 0.000 claims description 4
- 244000241872 Lycium chinense Species 0.000 claims description 3
- 235000015468 Lycium chinense Nutrition 0.000 claims description 3
- 206010034960 Photophobia Diseases 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- 241001164374 Calyx Species 0.000 claims description 2
- 235000002710 Ilex cornuta Nutrition 0.000 claims description 2
- 241001310146 Ilex cornuta Species 0.000 claims description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 240000007651 Rubus glaucus Species 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 4
- 206010057315 Daydreaming Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 8
- 244000235659 Rubus idaeus Species 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000027993 eye symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010047513 Vision blurred Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000008897 memory decline Effects 0.000 description 2
- 208000014733 refractive error Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- -1 DHA200 parts Chemical compound 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940069506 theanine 100 mg Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及含枸杞、菊花、γ‑氨基丁酸和茶氨酸的缓解视疲劳的组合物,属于医药健康领域。本发明提供了缓解视疲劳的组合物,其活性成分包括枸杞、菊花、γ‑氨基丁酸和茶氨酸。人群试用结果表明,本发明组合物不仅针对视疲劳眼睛局部症状,更能够明显改善不同程度视疲劳引起的精神神经症状,如注意力不集中、记忆力下降等,缓解视疲劳效果显著,具有广阔的市场前景。
Description
技术领域
本发明涉及含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物,属于医药健康领域。
背景技术
视疲劳又称眼疲劳,是以患者眼的自觉症状为基础,眼或全身器质性因素与精神(心理)因素相互交织的综合征,并非独立的眼病,因而常常被称为眼疲劳综合征(参见:1、李凤鸣.中华眼科学[M].北京:人民卫生出版社,2006,7~8;2、渠鸿颖等.视疲劳病因及其治疗的研究进展[J].中国中医眼科杂志,2003,14(1):59~61)。轻度视疲劳会在用眼后出现眼部酸、胀等眼部症状,休息后很快恢复;中度视疲劳会有明显的眼部症状,影响学习和工作;重度视疲劳除有明显的眼部症状和视作业不能持久外,还有记忆力减退、失眠等全身不适症状,干扰患者的视觉和生活质量,严重影响学习、工作和生活(参见:马越.花青素饮料缓解视疲劳作用的人体试验观察.中国食品学报[J].2015,8(15):8)。
大量的临床实践证明,屈光不正是视疲劳的主要原因之一,如远视、散光、近视患者,在未予矫正屈光不正时,看远或看近时动用较大的调节使睫状肌持续紧张造成患者的调节性视疲劳。另外,长时间近距离工作、工作或阅读环境照明不足等因素都可以导致人眼调节紧张,产生视疲劳。患者的精神状态和全身情况也与视疲劳的发生密切相关,精神压力大、体质衰弱的患者易产生视疲劳。
随着手机、平板电脑广泛进入人们的生活,人群全体用眼时间不断延长,近距离用眼强度增大,各年龄阶层视疲劳的发生率急速增多。能够改善视疲劳,并缓解由视疲劳带来的注意力、记忆力下降等问题的产品越来越受到消费者青睐。
目前,市面上改善视疲劳的产品通常仅针对蓝光损伤本身,对眼睛局部症状的改善效果不明显,而且并不能解决不同程度视疲劳引起的其他症状,如注意力不集中,记忆力下降等。因此,提供一种对视疲劳眼睛局部症状及精神神经症状缓解效果明显的产品,成为了一个亟待解决的问题。
发明内容
本发明的目的在于提供缓解视疲劳的组合物。
本发明提供了缓解视疲劳的组合物,活性成分包括枸杞、菊花、γ-氨基丁酸和茶氨酸。
进一步地,所述活性成分的重量配比为:枸杞500~12000份、菊花500~6000份、γ-氨基丁酸10~1000份、茶氨酸20~1000份。
进一步地,所述活性成分的重量配比为:枸杞6000~12000份、菊花3000~6000份、γ-氨基丁酸70~500份、茶氨酸100~400份。
优选地,所述活性成分的重量配比为:枸杞6000~12000份、菊花3000~6000份、γ-氨基丁酸100~300份、茶氨酸200~400份。
进一步地,所述枸杞为宁夏枸杞、中华枸杞、黑果枸杞、新疆枸杞、截萼枸杞、柱筒枸杞、云南枸杞、黄果枸杞、红枝枸杞、北方枸杞中一种或两种以上。
进一步地,所述菊花为杭菊、亳菊、贡菊、滁菊中一种或两种以上。
进一步地,活性成分还包括磷脂酰丝氨酸、DHA、覆盆子、薄荷、叶黄素、叶黄素酯、(3R,3'R)-二羟基-β-胡萝卜素中一种或两种以上的混合物。
进一步地,活性成分还包括磷脂酰丝氨酸10-1000份。
进一步地,活性成分还包括DHA10-1000份。
进一步地,活性成分还包括叶黄素和/或叶黄素酯0.6~25份。
进一步地,活性成分还包括(3R,3'R)-二羟基-β-胡萝卜素0.2~10份。
进一步地,活性成分还包括覆盆子500~1000份。
进一步地,活性成分还包括薄荷1000~3000份。
进一步地,所述的组合物是各重量配比的活性成分,加入可接受的辅料或者辅助性成分制备而成的食品、保健品或药品。
进一步地,所述食品、保健品或药品为口服形式。
进一步地,所述食品或保健品为糖果、饮料、饼干、面包、果冻或膳食补充剂。
本发明提供了所述组合物的制备方法,包括如下步骤:取各重量配比的活性成分,加入食品、保健品或药品中可接受的辅料或者辅助性成分,即得。
本发明提供了所述组合物在制备缓解视疲劳的食品、保健品或药品中的用途。
进一步地,所述食品、保健品或药品具有缓解视疲劳所致眼睛局部症状和/或精神神经症状的功效。
进一步地,所述眼睛局部症状为眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感或流泪。
进一步地,所述精神神经症状为注意力下降、记忆力减退、焦虑或失眠。
本发明提供了缓解视疲劳的组合物。人群试用结果表明,本发明组合物不仅针对视疲劳眼睛局部症状,更能够明显改善不同程度视疲劳引起的精神神经症状,如注意力不集中、记忆力下降等,缓解视疲劳效果显著,具有广阔的市场前景。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
本发明提供了缓解视疲劳的组合物,其活性成分包括枸杞、菊花、γ-氨基丁酸和茶氨酸。
本发明通过将枸杞、菊花、γ-氨基丁酸和茶氨酸组合使用,不仅能够有效改善由视疲劳带来的严重影响工作与生活的全身不适症状,包括可以减轻或缓解注意力及记忆力下降问题,试用者普遍反映使用后情绪焦虑缓解明显,由眼疲劳引发的睡眠问题也明显缓解,而且,人群试用试验表明,本发明组合物改善视疲劳眼睛局部症状的效果较枸杞和菊花更加明显,比如,眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感、流泪等症状都能够得到一定程度的改善,对视疲劳的治疗效果十分显著。
实施例1本发明糖果制备
原料按重量份数计:叶黄素酯6份;(3R,3'R)-二羟基-β-胡萝卜素2份;枸杞10000份;菊花3000份;覆盆子500份;薄荷1000份;γ-氨基丁酸300份,茶氨酸200份,DHA200份,磷酯酰丝氨酸200份。
制备方法:
1、按重量配比将枸杞、菊花、覆盆子、薄荷加入10倍的清水中煮沸15-30分钟,过滤,固体物质再加入同样量的水重复上述过程2次,收齐三次的滤液浓缩、干燥、粉碎后与(3R,3'R)-二羟基-β-胡萝卜素、γ-氨基丁酸、茶氨酸,DHA,磷酯酰丝氨酸,叶黄素酯混合均匀后加入糖浆搅拌均匀。
2、注模冷却成型后可按需制成凝胶软糖、压片糖、巧克力糖、硬糖、酥质糖、彩虹糖、充气糖果、胶基糖等类型。
实施例2本发明饮料的制备
原料按重量份数计:叶黄素酯12份;(3R,3'R)-二羟基-β-胡萝卜素4份;枸杞10000份;菊花6000份;覆盆子500份;薄荷2000份,茶氨酸200份,γ-氨基丁酸200份,磷酯酰丝氨酸200份,DHA50份。
制备方法:
1、按重量配比将枸杞、菊花、覆盆子、薄荷加入10倍的清水中煮沸15-30分钟,过滤,固体物质再加入同样量的水重复上述过程2次,收齐三次的滤液浓缩、干燥、粉碎。
2、按重量百分比将1的粉碎物和(3R,3'R)-二羟基-β-胡萝卜素、γ-氨基丁酸、茶氨酸,DHA,磷酯酰丝氨酸,叶黄素酯混合均匀后加入糖浆搅拌均匀。
3、按需制成各种饮料。
以下通过试验例证明本发明的有益效果。
试验例1本发明组合物缓解视疲劳及其相关症状的试用观察
本实验根据《视疲劳诊疗专家共识(2014年)》及国食药监保化[2012]107号《缓解视疲劳功能评价方法》制订视疲劳评定量表。征集试食者240名,男性108人,女性132人。分别于试食前后进行眼部症状及眼底检查,血、尿常规检查,肝、肾功能检查,症状询问、用眼情况调查,SAS评分,明视持久度和视力检查,远视力检查。眼睛局部症状:眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感、流泪7种症状中有任3种改善,且其他症状无恶化即判定眼睛局部症状改善,全身不适(包括注意力下降、记忆力减退、失眠)进行单项统计。计算两组症状改善例数和两组症状改善有效率。症状改善有效率(%)计算方法为症状改善例数/试食例数×100。将两组症状改善有效率进行统计学检验。
表1视疲劳评定量表
将受试者随机分为8组,每组30例,1组给予活性成分为枸杞6000mg菊花3000mg的糖果,2组给予活性成分为枸杞6000mg菊花3000mgγ-氨基丁酸500mg茶氨酸400mg的糖果,3组给予活性成分为枸杞500mg菊花6000mgγ-氨基丁酸10mg茶氨酸1000mg的糖果,4组给予活性成分为枸杞12000mg菊花500mgγ-氨基丁酸1000mg茶氨酸20mg的糖果,5组给予活性成分为枸杞6000mg菊花6000mgγ-氨基丁酸70mg茶氨酸400mg的糖果,6组给予活性成分为枸杞12000mg菊花3000mgγ-氨基丁酸500mg茶氨酸100mg的糖果,7组给予活性成分为枸杞6000mg菊花6000mgγ-氨基丁酸100mg茶氨酸400mg的糖果,8组给予活性成分为枸杞12000mg菊花3000mgγ-氨基丁酸300mg茶氨酸200mg的糖。各组糖果均按照实施例1方法制备,采用宁夏枸杞和杭菊。8组均连续服用60天(以上均为每日服用量)。分别于1天、60天统计眼睛局部症状改善的有效率,以及影响工作生活的视疲劳精神神经症状主要包括注意力下降、焦虑、失眠的变化,服用前后对比结果见下表:
表2缓解视疲劳症状有效率统计表
试验组1仅添加了枸杞和菊花,试用结果表明其具有缓解视疲劳眼睛局部症状的效果,服用60天后有效率达到30%,但起效较慢,短时间内没有明显效果。
试验组2~8在杞菊的基础上添加了γ-氨基丁酸和茶氨酸,结果明显加速了对眼睛局部症状的缓解效果,服用1天后显效更加明显,而且长期服用后对眼睛局部症状的缓解效果较试验组1更佳。此外,加入γ-氨基丁酸和茶氨酸的试验组还能明显改善注意力和失眠等全身症状。
本发明组合物能够全面改善视疲劳症状,且起效较市面上其它产品快,易于消费者坚持使用最终达到缓解视疲劳的目的。
Claims (14)
1.缓解视疲劳的组合物,其特征是:活性成分包括枸杞、菊花、γ-氨基丁酸和茶氨酸。
2.如权利要求1所述的组合物,其特征是:所述活性成分的重量配比为:枸杞500~12000份、菊花500~6000份、γ-氨基丁酸10~1000份、茶氨酸20~1000份。
3.如权利要求2所述的组合物,其特征是:所述活性成分的重量配比为:枸杞6000~12000份、菊花3000~6000份、γ-氨基丁酸70~500份、茶氨酸100~400份;优选地,所述活性成分的重量配比为:枸杞6000~12000份、菊花3000~6000份、γ-氨基丁酸100~300份、茶氨酸200~400份。
4.如权利要求1~3任意一项所述的组合物,其特征是:所述枸杞为宁夏枸杞、中华枸杞、黑果枸杞、新疆枸杞、截萼枸杞、柱筒枸杞、云南枸杞、黄果枸杞、红枝枸杞、北方枸杞中一种或两种以上。
5.如权利要求1~3任意一项所述的组合物,其特征是:所述菊花为杭菊、亳菊、贡菊、滁菊中一种或两种以上。
6.如权利要求1~5任意一项所述的组合物,其特征是:活性成分还包括磷脂酰丝氨酸、DHA、覆盆子、薄荷、叶黄素、叶黄素酯、(3R,3'R)-二羟基-β-胡萝卜素中一种或两种以上的混合物。
7.如权利要求1~6任意一项所述的组合物,其特征是:是各重量配比的活性成分,加入可接受的辅料或者辅助性成分制备而成的食品、保健品或药品。
8.如权利要求7所述的组合物,其特征是:所述食品、保健品或药品为口服形式。
9.如权利要求8所述的组合物,其特征是:所述食品或保健品为糖果、饮料、饼干、面包、果冻或膳食补充剂。
10.权利要求1~9任意一项所述组合物的制备方法,其特征是:包括如下步骤:取各重量配比的活性成分,加入食品、保健品或药品中可接受的辅料或者辅助性成分,即得。
11.权利要求1~9任意一项所述组合物在制备缓解视疲劳的食品、保健品或药品中的用途。
12.如权利要求11所述的用途,其特征是:所述食品、保健品或药品具有缓解视疲劳所致眼睛局部症状和/或精神神经症状的功效。
13.如权利要求12所述的用途,其特征是:所述眼睛局部症状为眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感或流泪。
14.如权利要求12所述的用途,其特征是:所述精神神经症状为注意力下降、记忆力减退、焦虑或失眠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810142339.3A CN108261472A (zh) | 2018-02-11 | 2018-02-11 | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810142339.3A CN108261472A (zh) | 2018-02-11 | 2018-02-11 | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108261472A true CN108261472A (zh) | 2018-07-10 |
Family
ID=62773910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810142339.3A Pending CN108261472A (zh) | 2018-02-11 | 2018-02-11 | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108261472A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109619257A (zh) * | 2019-01-23 | 2019-04-16 | 广州富诺健康科技股份有限公司 | 一种护眼软糖及其制备方法 |
CN111000095A (zh) * | 2019-12-26 | 2020-04-14 | 广州市志泰生物科技有限公司 | 一种具有助眠功能的γ-氨基丁酸饮品及其制备方法 |
CN117298142A (zh) * | 2023-11-28 | 2023-12-29 | 吉林华康食元生物科技有限公司 | 一种抗视疲劳的组合物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850064A (zh) * | 2006-02-26 | 2006-10-25 | 郭凌云 | 一种减轻紧张症状的制剂 |
CN101474311A (zh) * | 2009-01-22 | 2009-07-08 | 哈尔滨金道堂生物科技有限公司 | 缓解视疲劳的软胶囊及其制备方法 |
CN103584101A (zh) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | 一种用于缓解视疲劳的保健食品及其制备方法 |
CN104256817A (zh) * | 2014-09-19 | 2015-01-07 | 河南福森药业有限公司 | 一种缓解视疲劳的功能饮料及制备方法 |
CN105454605A (zh) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | 添加γ-氨基丁酸及茶氨酸的巧克力及其制备方法 |
-
2018
- 2018-02-11 CN CN201810142339.3A patent/CN108261472A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850064A (zh) * | 2006-02-26 | 2006-10-25 | 郭凌云 | 一种减轻紧张症状的制剂 |
CN101474311A (zh) * | 2009-01-22 | 2009-07-08 | 哈尔滨金道堂生物科技有限公司 | 缓解视疲劳的软胶囊及其制备方法 |
CN103584101A (zh) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | 一种用于缓解视疲劳的保健食品及其制备方法 |
CN104256817A (zh) * | 2014-09-19 | 2015-01-07 | 河南福森药业有限公司 | 一种缓解视疲劳的功能饮料及制备方法 |
CN105454605A (zh) * | 2015-12-11 | 2016-04-06 | 苏州泽达兴邦医药科技有限公司 | 添加γ-氨基丁酸及茶氨酸的巧克力及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109619257A (zh) * | 2019-01-23 | 2019-04-16 | 广州富诺健康科技股份有限公司 | 一种护眼软糖及其制备方法 |
CN111000095A (zh) * | 2019-12-26 | 2020-04-14 | 广州市志泰生物科技有限公司 | 一种具有助眠功能的γ-氨基丁酸饮品及其制备方法 |
CN117298142A (zh) * | 2023-11-28 | 2023-12-29 | 吉林华康食元生物科技有限公司 | 一种抗视疲劳的组合物及其制备方法和应用 |
CN117298142B (zh) * | 2023-11-28 | 2024-01-30 | 吉林华康食元生物科技有限公司 | 一种抗视疲劳的组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101595977B (zh) | 有益于眼睛明视持久度的配方食品及其应用 | |
CN102763847B (zh) | 一种具有缓解视疲劳的保健食品及其制备方法 | |
CN101856118A (zh) | 一种缓解视疲劳的保健食品及其制备方法 | |
CN104432036B (zh) | 缓解视疲劳的保健营养组合物及其制备方法与应用 | |
CN108078972A (zh) | γ-氨基丁酸在制备缓解视疲劳的食品、保健品或药品中的用途 | |
CN108261472A (zh) | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 | |
CN108294305A (zh) | 含原花青素的缓解视疲劳组合物 | |
CN108042652A (zh) | 含枸杞、菊花和γ-氨基丁酸的缓解视疲劳的组合物 | |
CN108157575A (zh) | 一种缓解视疲劳的压片糖果及其制备方法与应用 | |
CN108159036A (zh) | 含茶氨酸、磷脂酰丝氨酸和原花青素的缓解视疲劳的组合物 | |
CN103417733A (zh) | 一种缓解视疲劳的药物组合物 | |
CN112715729A (zh) | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 | |
CN100486456C (zh) | 一种用于缓解视疲劳的保健食品及其制备方法 | |
CN108354918A (zh) | 含茶氨酸、γ-氨基丁酸和原花青素的缓解视疲劳的组合物 | |
CN108324705A (zh) | 含茶氨酸、γ-氨基丁酸和花青素的缓解视疲劳的组合物 | |
CN113826894A (zh) | 一种缓解视疲劳胶囊及其制备方法 | |
CN108185427A (zh) | 含鱼眼、茶氨酸和磷脂酰丝氨酸的缓解视疲劳的组合物 | |
CN102488266B (zh) | 叶黄素木糖醇营养饮品及其制备方法 | |
CN108210640A (zh) | 含茶叶提取物的缓解视疲劳组合物 | |
CN108078974A (zh) | 含茶氨酸、γ-氨基丁酸和虾青素的缓解视疲劳的组合物 | |
CN112385770A (zh) | 一种鸡蛋面及其制备方法 | |
CN108057074A (zh) | 含枸杞、菊花和茶氨酸的缓解视疲劳的组合物 | |
CN108338364A (zh) | 含茶氨酸和虾青素的缓解视疲劳的组合物 | |
CN108159188A (zh) | 含枸杞、菊花、磷脂酰丝氨酸和茶氨酸的缓解视疲劳的组合物 | |
CN108433108A (zh) | 一种六红素制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180710 |
|
RJ01 | Rejection of invention patent application after publication |